Imaging of amyloid burden and distribution in cerebral amyloid angiopathy

Annals of Neurology

Volumn 62, Issue 3, 2007, Pages 229-234

  Johnson, Keith A ^a,b   Gregas, Matt ^c   Becker, John A ^a   Kinnecom, Catherine ^a   Salat, David H ^a,b   Moran, Erin K ^a   Smith, Erin E ^a,b   Rosand, Jonathan ^a,b   Rentz, Dorene M ^a,b   Klunk, William E ^d   Mathis, Chester A ^d   Price, Julie C ^d   DeKosky, Steven T ^d   Fischman, Alan J ^a,b   Greenberg, Steven M ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; BINDING PROTEIN; PITTSBURGH COMPOUND B; UNCLASSIFIED DRUG;

ADULT; ALZHEIMER DISEASE; AMYLOIDOSIS; ARTICLE; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; FEMALE; HUMAN; MALE; NON INVASIVE PROCEDURE; OCCIPITAL LOBE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; STROKE; VASCULAR AMYLOIDOSIS;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANILINE COMPOUNDS; BIOPSY; CEREBRAL AMYLOID ANGIOPATHY; CEREBRAL HEMORRHAGE; COHORT STUDIES; EDUCATION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; OCCIPITAL LOBE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; THIAZOLES;

EID: 34948819200     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.21164     Document Type: Article

References (44)

1. Jellinger KA. Alzheimer disease and cerebrovascular pathology: an update. J Neural Transm 2002;109:813-836.
2. Vinters HV. Cerebral amyloid angiopathy. A critical review. Stroke 1987;18:311-324.
3. Greenberg SM, Gurol ME, Rosand J, Smith EE. Amyloid angiopathy-related vascular cognitive impairment. Stroke 2004; 35:2616-2619.
4. Nicoll JA, Wilkinson D, Holmes C, et al. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003;9:448-452.
5. Greenberg SM, Bacskai BJ, Hyman BT. Alzheimer disease's double-edged vaccine. Nat Med 2003;9:389-390.
6. Ferrer I, Boada Rovira M, Sanchez Guerra ML, et al. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol 2004;14:11-20.
7. Mathis CA, Wang Y, Holt DP, et al. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 2003;46:2740-2754.
8. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimers disease with Pittsburgh Compound-B. Ann Neurol 2004;55:306-319.
9. Bacskai BJ, Hickey GA, Skoch J, et al. Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-beta ligand in transgenic mice. Proc Natl Acad Sci U S A 2003;100:12462-12467.
10. Bacskai B, Frosch MP, Freeman S. Molecular imaging with Pittsburgh compound B confirmed at autopsy. Arch Neurol 2007;64:1-4.
11. Vinters HV, Gilbert JJ. Cerebral amyloid angiopathy: incidence and complications in the aging brain. II. The distribution of amyloid vascular changes. Stroke 1983;14:924-928.
12. Masuda J, Tanaka K, Ueda K, Omae T. Autopsy study of incidence and distribution of cerebral amyloid angiopathy in Hisayama, Japan. Stroke 1988;19:205-210.
13. Tomonaga M. Cerebral amyloid angiopathy in the elderly. J Am Geriatr Soc 1981;29:151-157.
14. Rosand J, Muzikansky A, Kumar A, et al. Spatial clustering of hemorrhages in probable cerebral amyloid angiopathy. Ann Neurol 2005;58:459-462.
15. O'Donnell HC, Rosand J, Knudsen KA, et al. Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage. N Engl J Med 2000;342:240-245.
16. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994.
17. Greenberg SM, Vonsattel JP. Diagnosis of cerebral amyloid angiopathy. Sensitivity and specificity of cortical biopsy. Stroke 1997;28:1418-1422.
18. Knudsen KA, Rosand J, Karluk D, Greenberg SM. Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria. Neurology 2001;56:537-539.
19. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
20. Shapiro AM, Benedict RH, Schretlen D, Brandt J. Construct and concurrent validity of the Hopkins Verbal Learning Test-revised. Clin Neuropsychol 1999;13:348-358.
21. Grober E, Buschke H, Crystal H, et al. Screening for dementia by memory testing. Neurology 1988;38:900-903.
22. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimers disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
23. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412-2414.
24. Logan J, Fowler JS, Volkow ND, et al. Graphical analysis of leversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 1990;10:740-747.
25. Logan J, Fowler JS, Volkow ND, et al. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 1996;16:834-840.
26. Price JC, Klunk WE, Lopresti BJ, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab 2005;25:1528-1547.
27. Lopresti BJ, Klunk WE, Mathis CA, et al. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med 2005;46:1959-1972.
28. Mintun MA, Larossa GN, Sheline YI, et al. [11C]PIB in a non-demented population: potential antecedent marker of Alzheimer disease. Neurology 2006;67:446-452.
29. Archer HA, Edison P, Brooks DJ, et al. Amyloid load and cerebral atrophy in Alzheimer's disease: an (11)C-PIB position emission tomography study. Ann Neurol 2006;60:145-147.
30. Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006;59:512-519.
31. Thal DR, Rub U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002;58:1791-1800.
32. Kyriakides T, Silbert PL, Kakulas BA. Cerebral amyloid angiopathy and intracerebral hemorrhage with special reference to the pons. Clin Neuropathol 1994;13:71-76.
33. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 2002;15:273-289.
34. Friston KJ, Holmes AP, Worsley KJ. Statistical parametric maps in functional imaging: a general lineal approach. Human Brain Mapping 1995;2:189-210.
35. Itoh Y, Yamada M, Hayakawa M, et al. Cerebral amyloid angiopathy: a significant cause of cerebellar as well as lobar cerebral hemorrhage in the elderly. J Neurol Sci 1993;116:135-141.
36. Gravina SA, Ho L, Eckman CB, et al. Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43). J Biol Chem 1995;270:7013-7016.
37. Smith EE, Gurol ME, Eng JA, et al. White matter lesions, cognition, and recurrent hemorrhage in lobar intracerebral hemorrhage. Neurology 2004;63:1606-1612.
38. Braak H, Braak E, Kalus P. Alzheimer's disease: areal and laminar pathology in the occipital isocortex. Acta Neuropathol (Berl) 1989;77:494-506.
39. Weller RO, Nicoll JA. Cerebral amyloid angiopathy: both viper and maggot in the brain. Ann Neurol 2005;58:348-350.
40. Small GW, Kepe V, Ercoli LM, et al. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med 2006; 355:2652-2663.
41. Gurol ME, Irizarry MC, Smith EE, et al. Plasma beta-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy. Neurology 2006;66:23-29.
42. Haglund M, Englund E. Cerebral amyloid angiopathy, white matter lesions and Alzheimer encephalopathy - a histopathological assessment. Dement Geriatr Cogn Disord 2002;14:161-166.
43. Haglund M, Passant U, Sjobeck M, et al. Cerebral amyloid angiopathy and cortical microinfarcts as putative substrates of vascular dementia. Int J Geriatr Psychiatry 2006;21:681-687.
44. Salat DH, Smith EE, Tuch DS, et al. White matter alterations in cerebral amyloid angiopathy measured by diffusion tensor imaging. Stroke 2006;37:1759-1764.